Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Jun 19, 2022 9:10am
238 Views
Post# 34767391

Trolls...

Trolls.......now infecting this board. Please put them on ignore.

In other news, covid cases are rising across Europe and parts of the Middle East, Africa and Asia. While it's winter in the Southern Hemisphere these rises as summer approaches in the Northern Hemisphere suggest a potentially ominous Autumn. In France infections have doubled week over week.

While hospitalizations remain comparatively low many will still want to know what they may be infected with. While AcuVid is certainly late there is no indication that testing is not the diagnostic tool of choice at least until the beginning of 2023 ...and even then only if the predicted new winter waves don't materialize.

Will this finally be the week? It would be great to have an answer before quarterly financials are released in less than two weeks.

GLTE!!!
<< Previous
Bullboard Posts
Next >>